AbbVie Inc. (ABBV) Dividend Safety
- Dividend payout ratio · 12 months: Value 189.83%; Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | 189.83% | Cash dividends paid / net income. Period ending 2026-06-30. $11.98B ÷ $6.31B × 100 ≈ 189.83% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | 11.98B USD | Payments of Dividends |
| Net income · 12 months | 6.31B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | $11.98B | $6.31B | 189.83% |
| 2026-03-31 | $11.82B | $3.63B | 325.12% |
| 2025-12-31 | $11.66B | $4.23B | 275.84% |
| 2025-09-30 | $11.50B | $2.39B | 481.49% |
| 2025-06-30 | $11.34B | $3.76B | 301.30% |
| 2025-03-31 | $11.18B | $4.20B | 266.46% |
| 2024-12-31 | $11.03B | $4.28B | 257.71% |
| 2024-09-30 | $10.90B | $5.12B | 212.79% |
| 2024-06-30 | $10.78B | $5.34B | 201.82% |
| 2024-03-31 | $10.65B | $5.99B | 177.71% |
| 2023-12-31 | $10.54B | $4.86B | 216.72% |
| 2023-09-30 | $10.42B | $6.51B | 159.95% |
| 2023-06-30 | $10.30B | $8.69B | 118.55% |
| 2023-03-31 | $10.18B | $7.58B | 134.19% |
| 2022-12-31 | $10.04B | $11.84B | 84.85% |
| 2022-09-30 | $9.85B | $13.41B | 73.48% |
| 2022-06-30 | $9.66B | $12.64B | 76.46% |
| 2022-03-31 | $9.46B | $12.48B | 75.85% |
| 2021-12-31 | $9.26B | $11.54B | 80.24% |
| 2021-09-30 | $9.05B | $7.53B | 120.10% |
| 2021-06-30 | $8.83B | $6.66B | 132.57% |
| 2021-03-31 | $8.28B | $5.16B | 160.40% |
| 2020-12-31 | $7.72B | $4.62B | 167.16% |
| 2020-09-30 | $7.21B | $7.38B | 97.68% |
| 2020-06-30 | $6.70B | $6.96B | 96.32% |
| 2020-03-31 | $6.54B | $8.44B | 77.54% |
| 2019-12-31 | $6.37B | $7.88B | 80.77% |
| 2019-09-30 | $6.22B | $3.25B | 191.15% |
| 2019-06-30 | $6.09B | $4.12B | 147.94% |
| 2019-03-31 | $6.03B | $5.36B | 112.52% |
| 2018-12-31 | $5.58B | $5.69B | 98.12% |
| 2018-09-30 | $5.16B | $7.57B | 68.20% |
| 2018-06-30 | $4.72B | $6.45B | 73.25% |
| 2018-03-31 | $4.22B | $6.38B | 66.09% |
| 2017-12-31 | $4.11B | $5.31B | 77.36% |
| 2017-09-30 | $4.01B | $6.65B | 60.32% |
| 2017-06-30 | $3.92B | $6.62B | 59.21% |
| 2017-03-31 | $3.82B | $6.31B | 60.54% |
| 2016-12-31 | $3.72B | $5.95B | 62.44% |
| 2016-09-30 | $3.62B | (m) | (m) |
| 2016-06-30 | $3.54B | (m) | (m) |
| 2016-03-31 | $3.43B | (m) | (m) |
| 2015-12-31 | $3.29B | (m) | (m) |
| 2015-09-30 | $3.13B | (m) | (m) |
| 2015-06-30 | $2.95B | (m) | (m) |
| 2015-03-31 | $2.81B | (m) | (m) |
| 2014-12-31 | $2.66B | (m) | (m) |
| 2014-09-30 | $2.63B | (m) | (m) |
| 2014-06-30 | $2.60B | (m) | (m) |
| 2014-03-31 | $2.56B | (m) | (m) |
| 2013-12-31 | $2.56B | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |